Sandre Svatun Lirhus1, Hans Olav Melberg1, Marte Lie Høivik2, Bjørn Moum2
1 Department of Health Management and Health Economics, University of Oslo2 Department of Gastroenterology, Oslo University Hospital, Ullevål
During the last decade, several new and expensive drugs (including TNFα inhibitors and anti-integrins) have been introduced in inflammatory bowel disease (IBD) treatment. Little is known about the overall treatment pattern for these new biologic pharmaceuticals. The aim of this study was to describe variations in the use of biologics for IBD in different hospital regions in Norway.
Data and methods
Data was collected from the Norwegian Patient Registry and includes information about every individual hospital treatment episode for IBD patients (ICD codes K50 and K51) from 2008 to 2015. The date of diagnosis was set to the earliest observation in which the individual was observed with a Crohn’s disease or ulcerative colitis treatment episode. In order to identify only newly diagnosed patients, the results were calculated for patients who were diagnosed between 2012 and 2014. The analysis was broken down by disease and each of the four geographic health regions in Norway.
The sample contained information on 97353 hospital events for 10486 patients (66% with UC and 35% with CD) and on average there were 3495 new IBD patients diagnosed each year (2012-14). One year after being diagnosed, the percentage of patients with Crohn’s disease who had received a biologic pharmaceutical ranged from 13.6% to 19.3% in the different health regions. For patients with ulcerative colitis, the percentages ranged from 3.7% to 7.4%. Broken down by each health region the percentage of patients with CD (UC) having received a biologic after one year were: Central: 13.6% (3.7%), West: 17.5 (5.8%), South-East: 18.3% (7.4%), North: 19.3% (6.4%).
The overall pattern was that three of the regions had very similar treatment patterns for the use of biologics (West, South-East, North), while one region (Central) consistently had a lower percentage of patients who had received biologics one year after receiving the diagnosis.